Home › Research › Costs and economics
Cost-effectiveness of multimodal intervention for the prevention of dementia in Japan
Naoki Takashi, Shosuke Ohtera, Yujiro Kuroda, Hidenori Arai, Takashi Sakurai, J-MINT investigators. The journal of prevention of Alzheimer's disease, 2026-01-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Background This analysis evaluated the potential cost-effectiveness of the Japan-Multimodal Intervention Trial for the prevention of dementia (J-MINT), targeting older adults with mild cognitive impairment (MCI) from a societal perspective. Methods Using a time-dependent cohort state-transition model, we estimated the long-term economic impact of J-MINT. Costs included medical, long-term, and informal care. Incremental cost-effectiveness ratios (ICERs) were calculated based on simulated costs and quality-adjusted life years (QALYs). Results The base-case analysis indicated that the J-MINT was dominant, demonstrating cost saving and more effective compared to usual care. Over 35 years, J-MINT was projected to achieve cost savings of JPY 452,826 per person and a gain of 0.08 QALYs. Deterministic and probabilistic sensitivity analyses confirmed the robustness of these findings. Scenario analysis suggested that targeting APOE ε4 carriers or individuals with high adherence to exercise yielded even greater benefits. Conclusion J-MINT demonstrates cost-effectiveness by reducing overall care costs while improving QALYs in individuals with MCI.
What this study adds
Evidence grade: Moderate
This modelling study projected that the J-MINT multimodal lifestyle program for older adults with mild cognitive impairment would save costs and gain quality-adjusted life-years over 35 years compared with usual care. Reported effect size: Incremental cost -452,826 JPY per person and +0.08 QALYs over 35 years (dominant vs usual care).
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Takashi, N., Ohtera, S., Kuroda, Y., Arai, H., Sakurai, T., & J-MINT investigators. (2026). Cost-effectiveness of multimodal intervention for the prevention of dementia in Japan. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2025.100460
Vancouver
Takashi N, Ohtera S, Kuroda Y, Arai H, Sakurai T, J-MINT investigators. Cost-effectiveness of multimodal intervention for the prevention of dementia in Japan. The journal of prevention of Alzheimer's disease. 2026. doi:10.1016/j.tjpad.2025.100460. PMID: 41478834.
BibTeX
@article{takashi2026-41478834,
author = {Takashi, Naoki and Ohtera, Shosuke and Kuroda, Yujiro and Arai, Hidenori and Sakurai, Takashi and {J-MINT investigators}},
title = {{Cost-effectiveness of multimodal intervention for the prevention of dementia in Japan}},
journal = {The journal of prevention of Alzheimer's disease},
year = {2026},
doi = {10.1016/j.tjpad.2025.100460},
pmid = {41478834},
url = {https://doi.org/10.1016/j.tjpad.2025.100460}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results The base-case analysis indicated that the J-MINT was dominant, demonstrating cost saving and more effective compared to usual care.
- Deterministic and probabilistic sensitivity analyses confirmed the robustness of these findings.
- Scenario analysis suggested that targeting APOE ε4 carriers or individuals with high adherence to exercise yielded even greater benefits.
- Conclusion J-MINT demonstrates cost-effectiveness by reducing overall care costs while improving QALYs in individuals with MCI.
Why it matters
This modelling study projected that the J-MINT multimodal lifestyle program for older adults with mild cognitive impairment would save costs and gain quality-adjusted life-years over 35 years compared with usual care. These are simulated long-term projections, and the authors note that targeting APOE ε4 carriers or people who adhere well to exercise could yield even greater benefits.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designmodelling
- Effect sizeIncremental cost -452,826 JPY per person and +0.08 QALYs over 35 years (dominant vs usual care)
- Evidence strengthModerate
Limitations
Long-horizon extrapolation from an 18-month trial; assumes intervention effects persist; Japanese cost structure; authors include the trial investigators.
How this study scored 39/100
Published in a peer-reviewed journal, and it is a computer model rather than new measurements. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 38 of the 98 points we could judge it on, which is 39 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 3 / 12 | A computer model rather than new measurements |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Takashi Sakurai: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | National Center for Geriatrics and Gerontology: institution h-index 249 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41478834) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 38 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 38 of the 98 points we could judge it on is 39 out of 100. |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.tjpad.2025.100460
- PubMed: 41478834
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Costs and economics from nearby years
Also tagged “prevalence”
1,223 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,223 tagged studies.